Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
162.40    0.80 (0.50%)
Bid:
161.40
Ask:
163.80
Spread: 2.40 (1.487%)
Market Cap: £276.19m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Second tranche of share buyback programme

1 May 2026 07:00

RNS Number : 6884C
McBride PLC
01 May 2026
Β 

McBride plc

Β 

Second tranche of share buyback programme

Β 

McBride plc (the "Company"), the leading European manufacturer and supplier of private label and contract manufactured products for the domestic household and professional cleaning/hygiene markets, today announces the commencement of the second tranche of its share buyback programme to purchase ordinary shares of 10 pence each in the Company ("Ordinary Shares"), as launched on 1 December 2025 (the "Programme").

Purchases under the first tranche of the Programme commenced on 1 December 2025 and continued until 30 April 2026.Β Under the first tranche, between 1 December 2025 and 30 April 2026, the Company repurchased 3,236,565Β Ordinary Shares for an aggregate consideration of approximately Β£4.5 million.

The Company announces that the second tranche of the Programme of up to Β£15.5 million (being the balance of the Β£20 million maximum amount of the Programme less the aggregate consideration paid under the first tranche of the Programme) will commence today (the "Second Tranche"). The Second Tranche is structured in two phases. In respect of the first phase, the Company has entered into a non-discretionary agreement with Investec Bank plc ("Investec") to act as riskless principal in relation to the purchase of Ordinary Shares, and the subsequent sale of such Ordinary Shares to the Company. The second phase will be undertaken by Peel Hunt LLP ("Peel Hunt", together with Investec, the "Brokers"). The Company has entered into a non-discretionary agreement with Peel Hunt to act as riskless principal in relation to the purchase of Ordinary Shares, and the subsequent sale of such Ordinary Shares to the Company.

Purchases of Ordinary Shares under the Second Tranche are expected to commence on 1 May 2026 and to be completed by no later than 30 September 2026. The Company intends to announce any purchases under the Programme on a weekly basis from the commencement of the Second Tranche of the Programme.

The Brokers will each make trading decisions in relation to the Programme independently of the Company. Any purchase of Ordinary Shares by the Brokers contemplated by this announcement will be carried out on the London Stock Exchange. Any purchases of Ordinary Shares by the Company under the Programme will be carried out on the London Stock Exchange.

The purpose of the Programme is to reduce the share capital of the Company by returning surplus capital to shareholders. Ordinary Shares purchased under the Second Tranche will be cancelled. These arrangements are in accordance with the Company's general authority to repurchaseΒ up to 17,401,528 Ordinary Shares granted at its 2025 Annual General Meeting. The Second Tranche will also be conducted within certain pre-set parameters, in accordance with Chapter 9 of the Listing Rules and within the parameters prescribed by the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018).

From time to time, the Board will assess the progress of this Programme in light of the financial situation of the Company and its capital allocation needs.

For further information, please contact:

Β 

McBride plc

Via TEAM LEWIS

Chris Smith, Chief Executive Officer

Mark Strickland, Chief Financial Officer

TEAM LEWIS

McBride@teamlewis.com

Hannah Scott

Galyna Kulachek

+44 (0)20 7802 2634

+44 (0)20 7802 2617

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCAKKBPOBKDBQN
Date   Source Headline
17th Sep 20247:00 amRNSFinal Results
16th Jul 20247:00 amRNSFull Year Trading Update
3rd Jul 20242:33 pmRNSHolding(s) in Company
14th Jun 20247:00 amRNSGrant and vesting of RSU Awards to PDMR
2nd May 20249:21 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSTrading Update
8th Apr 202411:24 amRNSHolding(s) in Company
8th Apr 202411:22 amRNSHolding(s) in Company
5th Apr 20249:53 amRNSHolding(s) in Company
28th Mar 20243:20 pmRNSDirector/PDMR Shareholding
25th Mar 20241:52 pmRNSDirector/PDMR Shareholding
13th Mar 20247:00 amRNSCapital Markets Day
28th Feb 20242:30 pmRNSDirector/PDMR Shareholding
27th Feb 20247:00 amRNSHalf-year Report
16th Jan 20247:00 amRNSTrading Update
13th Dec 20231:47 pmRNSDirector/PDMR Shareholding
20th Nov 20235:55 pmRNSDirector/PDMR Shareholding
20th Nov 20235:39 pmRNSResult of AGM
20th Nov 20237:00 amRNSAGM Trading Update
25th Oct 202310:22 amRNSTermination of ‘upside sharing’ mechanism
19th Oct 20237:00 amRNSTrading Update
17th Oct 20235:42 pmRNSPosting of ARA and Notice of AGM
4th Oct 20235:24 pmRNSVesting of RSU Awards
29th Sep 20237:00 amRNSDirector/PDMR Shareholding
22nd Sep 20235:33 pmRNSDirector/PDMR Shareholding
21st Sep 202310:54 amRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSFinal Results
14th Jul 20237:00 amRNSFull year trading update
13th Jun 20237:00 amRNSDirector/PDMR Shareholding
31st May 20235:31 pmRNSDirectorate Change
25th May 20239:38 amRNSDirector Declaration
2nd May 20237:00 amRNSDirector/PDMR Shareholding
25th Apr 20237:00 amRNSTrading Update
11th Apr 20232:08 pmRNSDirector/PDMR Shareholding
3rd Apr 20232:39 pmRNSDirector/PDMR Shareholding
31st Mar 202312:27 pmRNSDirector/PDMR Shareholding
21st Mar 20235:59 pmRNSDirector/PDMR Shareholding
28th Feb 20237:00 amRNSHalf-year Report
1st Feb 20234:40 pmRNSSecond Price Monitoring Extn
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20238:46 amRNSDirector Declaration
17th Jan 20237:00 amRNSTrading Update
11th Jan 20239:01 amRNSDirector Declaration
22nd Dec 20224:23 pmRNSDirector/PDMR Shareholding
13th Dec 20222:51 pmRNSDirector/PDMR Shareholding
16th Nov 20224:42 pmRNSAGM Statement
16th Nov 20227:00 amRNSAGM Trading Update
17th Oct 20227:00 amRNSAnnual Report 2022 and Annual General Meeting 2022
5th Oct 20225:55 pmRNSDirector/PDMR Shareholding
3rd Oct 20225:07 pmRNSRedemption of B Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.